Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital)(Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital))

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名-

靶点-

作用机制

免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤

在研适应症

实体瘤

非在研适应症-

原研机构

Johns Hopkins All Children's Hospital

在研机构

Johns Hopkins All Children's Hospital

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital) 相关的临床试验

NCT06047977 / Not yet recruiting临床1期IIT

Tumor Infiltrating Lymphocytes in Pediatric Malignant Solid Tumors: A Prospective Biobanking Study and Phase I Clinical Trial

Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors.
Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors

开始日期2024-10-01

申办/合作机构

Johns Hopkins All Children's Hospital

100 项与 Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor Infiltrating Lymphocyte Therapy(Johns Hopkins All Children's Hospital) 相关的药物交易

登录后查看更多信息